Coronary thrombosis

SonoVascular Enters into Strategic Collaboration with Lantheus Holdings, Inc. for Use of Microbubbles in Combination with SonoThrombectomy™ System for Treatment of Venous Thromboembolism

Retrieved on: 
Thursday, May 2, 2024
Safety, VTE, FIH, Partnership, Pulmonary embolism, Patient, DVT, Catheter, Microbubble, Vein, Coronary thrombosis, Deep vein thrombosis

VTE is a condition that occurs when a blood clot forms in a deep vein, resulting in DVT.

Key Points: 
  • VTE is a condition that occurs when a blood clot forms in a deep vein, resulting in DVT.
  • The microbubbles are activated by intravascular ultrasound and will be investigated in ongoing pre-clinical and upcoming clinical studies.
  • The SonoThrombectomy System has been engineered to address and overcome the deficiencies and limitations of current interventional devices.
  • Additionally, upon completion of a FIH study, SonoVascular has an option to enter into a long-term exclusive commercial supply agreement with Lantheus.

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

Retrieved on: 
Tuesday, April 16, 2024
Research, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, MVT, Sale, FDA, Pain, Interventional radiology, Patient, Phase, Risk, Ischemia, Pancreatic cancer, Prevalence, Thrombosis, LAPC, Radiology, MD, Venous thrombosis, Columbia University, Society of Interventional Radiology, Vein, SIR, Associate, TAMP, Coronary thrombosis, Medical imaging

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today highlights a presentation of a clinical data abstract at the recent 2024 Society of Interventional Radiology (SIR) Annual Scientific Meeting, held March 23-27, 2024 in Salt Lake City, Utah.
  • Clinical data was presented by David Sperling, MD, Associate Professor of Radiology at Columbia University Irving Medical Center in New York.
  • The data presentation highlighted that of the 25 patients randomized to the TAMP therapy, 6 failed to complete all 8 planned procedures due to thrombosis of the targeted arterial artery.
  • The first interim analysis in the Phase III TIGeR-PaC study was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study.

National Blood Clot Alliance Names Corewell Health a Center of Excellence

Retrieved on: 
Wednesday, April 10, 2024
Education, Patient, Hospital, VTE, Certification, NBCA, COE, Butterworth Hospital, Pulmonary embolism, Survivor, DVT, National Blood Clot Alliance, Health, Deep vein thrombosis, Coronary thrombosis, Nursing

PHILADELPHIA, April 10, 2024 /PRNewswire/ -- National Blood Clot Alliance ® (NBCA) today announced that Corewell Health™ Grand Rapids Hospitals – Butterworth Hospital has been named the inaugural NBCA Center of Excellence in the United States.

Key Points: 
  • PHILADELPHIA, April 10, 2024 /PRNewswire/ -- National Blood Clot Alliance ® (NBCA) today announced that Corewell Health™ Grand Rapids Hospitals – Butterworth Hospital has been named the inaugural NBCA Center of Excellence in the United States.
  • By designating Corewell Health a Center of Excellence, we are acknowledging its commitment to both clinical excellence and patient education," said Board Member and NBCA Committee Chair Justin Crockett.
  • In designating Corewell Health as an NBCA Center of Excellence, the committee highlighted both the qualitative and quantitative multidisciplinary, systematic approach to DVT and PE treatment.
  • "This formal recognition speaks highly of the demonstrated excellence of Corewell Health's program treating patients with acute and chronic VTE," said Alejandro Quiroga, M.D., president, Corewell Health in West Michigan.

Inari Medical Strengthens Senior Leadership Team with Addition of Two Executives

Retrieved on: 
Tuesday, April 2, 2024
Moses Austin, Ohio State University, Edwards Lifesciences, Education, Patient, Global strategy, SVP, Coronary thrombosis, Business development, Radiology, University, Doctors Hospital, Faculty, Senior, Abstract, MD Anderson Cancer Center, Hospital, MitraClip, Baptist Hospital, Interventional radiology, Health, Global marketing

IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.

Key Points: 
  • IRVINE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), today announced the appointment of Tim Benner as Senior Vice President of U.S.
  • Dr. Niekamp will be instrumental in advancing Inari’s mission to improve patient care through physician education and new device development.
  • Mr. Benner joins Inari with more than 16 years of senior leadership experience with high-growth and transformational medical technology companies.
  • We are honored to add his talents to our Medical Affairs team,” said Dr. Thomas Tu, Chief Medical Officer of Inari.

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Retrieved on: 
Thursday, March 28, 2024
CSL Vifor, Thrombosis, Myocardial infarction, Conference, Organization, Tablet, Caregiver, Anemia, Physician, CKD, Webcast, Patient, Coronary thrombosis, Stroke, AKBA, Death, Renal Support Network, Kidney disease, Nephrology, Kidney, Chronic kidney disease, Dialysis, Division, Safety, Stanford University, Food, Hypoxia, FDA, Erythropoietin, Pharmaceutical industry

CAMBRIDGE, Mass., March 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries.

Key Points: 
  • "At Akebia we are committed to kidney patients, a dedication that has driven our team to achieve this milestone.
  • We believe this commitment uniquely positions the company to execute a successful launch designed to drive toward a potential new oral standard of care for dialysis patients."
  • Approximately 500,000 adult patients in the U.S. on dialysis suffer from anemia due to CKD1, which may be associated with many adverse clinical outcomes.
  • Today, most CKD patients are treated for anemia with injectable erythropoiesis-stimulating agents mostly administered at dialysis centers.

Global Pediatric Interventional Cardiology Market Forecast 2024-2030: PIC Market Forecast for 6.36% CAGR Between 2024 to 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024
General Health, Health, Cardiology, Heart, Incidence, Procedure, Catheter, Birth defect, Investment, Physician, Moyamoya disease, Congenital heart defect, Projection, VSD, Angioplasty, Prevalence, CHD, Coronary thrombosis, Atherectomy, Patient, Stent, Ventricular septal defect, CDC, Catheter ablation, Research, Medical imaging

The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.

Key Points: 
  • The Pediatric Interventional Cardiology Market is forecasted to reach US$ 3.91 Billion through 2030.
  • The pediatric interventional cardiology market proportion is expanding swiftly, driven by the rising prevalence of cardiac disorders in children and technological advancements.
  • The Stents segment is anticipated to dominate the global pediatric interventional cardiology market throughout the forecast period.
  • The comprehensive infrastructure of hospitals, coupled with their ability to provide diverse pediatric cardiology services, positions them as key contributors to the growth and development of the Pediatric Interventional Cardiology market.

Roche launches three new Factor Xa inhibitor coagulation tests to meet growing patient need

Retrieved on: 
Monday, February 12, 2024
Essential medicines, CE, Rivaroxaban, VTE, Anticoagulant, INR, Roche, Edoxaban, Direct factor Xa inhibitors, PAD, Stroke, Moyamoya disease, Risk, CAD, Ventricular fibrillation, Health, Patient, Labs, Coronary thrombosis, Diagnosis, Laboratory, Coronary artery disease

"Diseases such as CAD and PAD can have serious consequences and urgently need better diagnosis and treatment.

Key Points: 
  • "Diseases such as CAD and PAD can have serious consequences and urgently need better diagnosis and treatment.
  • "These numbers and our growing understanding of these diseases are leading to a sharp rise in global demand for direct oral anticoagulants.
  • We want to help labs meet this increased need for testing to better inform patient care.
  • These tests can be used for both assessing the anti-Xa activity of heparin therapy as well as the three authorised Factor Xa inhibitors.

Innova Vascular Announces Successful Early Commercial Use of Laguna Thrombectomy System™ in Patients

Retrieved on: 
Wednesday, February 7, 2024
Cardiology, Physician, Food and Drug Administration, Aspiration, Patient, UCLA, FDA, Nickel titanium, Food, System, Interventional radiology, Coronary thrombosis

IRVINE, Calif., Feb. 7, 2024 /PRNewswire/ -- Innova Vascular, Inc. today announced successful early commercial use of the company's Laguna Thrombectomy System™.

Key Points: 
  • IRVINE, Calif., Feb. 7, 2024 /PRNewswire/ -- Innova Vascular, Inc. today announced successful early commercial use of the company's Laguna Thrombectomy System™.
  • The Laguna Thrombectomy System encompasses two devices developed by Innova Vascular: the Malibu Aspiration Catheter™ System and the Laguna Clot Retriever™ System.
  • "We are extremely pleased with the early clinical performance of the system and look forward to expanding our product launch in the period ahead," said Sanjay Shrivastava, Ph.D., CEO of Innova Vascular.
  • "Successful use of the System marks an important milestone in our commitment to develop innovative technologies targeting large, underserved markets.

Inari Medical Announces Preliminary 2023 Revenue and 2024 Guidance

Retrieved on: 
Tuesday, January 9, 2024
Coronary thrombosis, Patient, Traction, Annual report, RCT, VTE, FLAME, Randomized controlled trial, Isabella Tree, Growth, Pharmaceutical industry

IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.

Key Points: 
  • IRVINE, Calif., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and full year 2023 revenue and established its 2024 financial guidance.
  • Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be at least $132.0 million, up approximately 22% year-over-year.
  • Preliminary unaudited revenue for the full year 2023 is expected to be at least $493.5 million, up approximately 29% over the full year 2022.
  • Further detail will be provided when Inari reports its financial results for the fourth quarter and full year 2023.

Endovascular Engineering's Hēlo™ Thrombectomy System Receives IDE Approval to Start ENGULF Pivotal Trial for the Treatment of Pulmonary Embolism

Retrieved on: 
Thursday, January 11, 2024
IDE, Coronary thrombosis, Patient, Cardiac catheterization, University, Interventional cardiology, Safety, VTE, MPH, Piedmont Hospital, Pulmonary embolism, Pharmaceutical industry

The approval of the IDE follows the successful completion of the company's 25-patient feasibility study.

Key Points: 
  • The approval of the IDE follows the successful completion of the company's 25-patient feasibility study.
  • "We are excited to be at the forefront of this innovative procedure with the completion of the ENGULF feasibility study.
  • This significant achievement sets the stage for definitive results in the ENGULF pivotal trial.
  • Embarking on our ENGULF pivotal trial is a significant step, further validating the system's safety and efficacy.